IUSM Alzheimer's Disease Drug Discovery Center

IUSM 阿尔茨海默病药物研发中心

• 批准号: 10250434
• 负责人: Bruce T Lamb
• 金额: $ 745.29万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250434
• 关键词: Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animal Disease Models; Basic Science; Biological Markers; Biology; Brain; Cause of Death; Clinical Research; Clinical Sciences; Clinical Trials Design; Communities; Custom; Data; Dimensions; Disease; Drug Targeting; Elements; Ensure; Feasibility Studies; Foundations; Generations; Genetic; Goals; Human Pathology; Immunization; Indiana; Institutes; Intervention; Investments; Lead; Methods; Mission; Modality; Modeling; Molecular; Nerve Degeneration; Neuroimmune; Pathway interactions; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Postdoctoral Fellow; Presenile Alzheimer Dementia; Probability; Process; Research; Research Personnel; Resources; Risk; Science; Scientist; Technology; Testing; Therapeutic; Time; Toxicology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Validation; Work; abeta accumulation; base; beta secretase; data access; data sharing; design; disability; drug candidate; drug development; drug discovery; experimental study; flexibility; gamma secretase; human disease; inhibitor/antagonist; innovation; insight; medical schools; novel; open data; physical property; pre-clinical; sharing platform; success; translational study; validation studies

The strategic goal of the Indiana University School of Medicine Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s disease (AD) target hypotheses (beyond Ab) with the goal of generating new classes of potential therapeutics. Specifically, the ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a world-class team of scientists and capabilities from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer’s Disease Center under the direction of Dr. Andy Saykin, the MODEL-AD consortium under the direction of Dr. Bruce Lamb, and the Longitudinal Early Onset Alzheimer’s Disease (LEAD) study under the direction of Dr. Liana Apostolova. The Specific Aims of the ADDD CENTER are: 1. Create a dynamic portfolio of well-characterized AD drug discovery targets representing novel intervention hypotheses that capitalize on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create high-quality and well-characterized lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment. 4. Create a robust and flexible data sharing platform to enable global researchers with data and target enablement packages to expand on the work of the ADDD CENTER.

印第安纳大学医学院阿尔茨海默病药物发现 (ADDD) 中心的战略目标是整合早期药物发现的复杂能力，并有助于对新兴阿尔茨海默病 (AD) 目标假设（超越 Ab）进行更广泛的研究，其目标是具体来说，ADDD 中心将成为 NIA AMP-AD 和 MODEL-AD 计划的战略和运营合作伙伴，这将提供药物发现能力，以桥接目标发现的基础工作。 (AMP-AD) 以及基于人类病理学、遗传学和转化生物标志物的 AD 动物模型中新发现的先导分子 (MODEL-AD) 为了完成 ADDD 中心的使命，我们组建了一支世界一流的科学家团队和团队。该团队来自印第安纳大学、普渡大学和印第安纳临床与转化科学研究所 (CTSI)，在阿尔茨海默病生物学、中枢神经系统药物发现和开发以及推动 ADDD 的核心发现技术方面拥有丰富的专业知识。拟建的 ADDD 中心的一个关键优势和独特优势是通过印第安纳大学医学院进行主要的科学协调和管理，具体来说，它通过与印第安纳大学医学院的共同存在，集中了对神经退行性研究的坚定而长期的承诺。在 Andy Saykin 博士的指导下，NIA 支持的印第安纳阿尔茨海默病中心、在 Bruce Lamb 博士的指导下的 MODEL-AD 联盟以及纵向早发阿尔茨海默病ADDD 中心的具体目标是： 1. 创建一个动态的 AD 药物发现目标组合，代表新颖的干预假设，利用基础研究和新兴领域的大量投资。 2. 进行先进的临床前靶标验证和支持研究，以优先考虑治疗发现的最佳机会 3. 为满足严格的里程碑标准并具有宝贵机会的优先靶标创建高质量且特征良好的先导分子。 4. 创建一个强大而灵活的数据共享平台，为全球研究人员提供数据和目标支持包，以扩展 ADDD 中心的工作。